SEGMENT REPORTING - Revenue (Details) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) segment	Sep. 30, 2021 USD ($)	Dec. 31, 2021 segment
Segment reporting
Number of segments | segment			2		1
Revenue recognition	$ 83,821	$ 52,061	$ 222,153	$ 155,207
Depreciation and amortization	14,167	11,346	42,488	33,568
Selling, general, and administrative	30,081	17,181	90,856	53,588
Operating Loss	(4,995)	(3,562)	(37,103)	(16,070)
Interest expense, net	(7,264)	(2,497)	(20,546)	(7,482)
Other expense, net	37	(1,071)	712	(1,653)
Loss Before Benefit for Income Taxes	(12,222)	(7,130)	(56,937)	(25,205)
Operating segments | Generics, Established Brands and Other
Segment reporting
Revenue recognition	71,219	52,061	198,057	155,207
EBITDA	22,099	17,030	52,103	53,529
Operating segments | Rare Disease
Segment reporting
Revenue recognition	12,602		24,096
EBITDA	(2,382)	(3,085)	(19,493)	(8,836)
Unallocated expenses
Segment reporting
Depreciation and amortization	(14,167)	(11,346)	(42,488)	(33,568)
Selling, general, and administrative	(10,545)	(6,161)	(27,225)	(27,195)
Operating Loss	(4,995)	(3,562)	(37,103)	(16,070)
Interest expense, net	(7,264)	(2,497)	(20,546)	(7,482)
Other expense, net	$ 37	$ (1,071)	$ 712	$ (1,653)